share_log

藥明生物：翌日披露報表

WUXI BIO: Next Day Disclosure Return

Hong Kong Stock Exchange ·  Apr 19 21:14
Summary by Futu AI
藥明生物技術有限公司（药明生物）於2024年4月19日完成一系列股份購回活動，並於翌日向香港聯合交易所有限公司披露相關變動。該公司在2023年12月7日至2024年4月19日期間，透過多次交易購回股份，但並未註銷這些股份。最後一次購回發生在2024年4月19日，當日購回1,570,000股，每股價格介乎HKD 12.62至HKD 12.8，總付出金額為HKD 19,920,430。自普通決議案通過以來，公司在香港聯交所購回的證券總數達93,157,000股，佔已發行股份的2.19275%。药明生物確認，所有購回活動均符合《主板上市規則》/《GEM上市規則》的規定。
藥明生物技術有限公司（药明生物）於2024年4月19日完成一系列股份購回活動，並於翌日向香港聯合交易所有限公司披露相關變動。該公司在2023年12月7日至2024年4月19日期間，透過多次交易購回股份，但並未註銷這些股份。最後一次購回發生在2024年4月19日，當日購回1,570,000股，每股價格介乎HKD 12.62至HKD 12.8，總付出金額為HKD 19,920,430。自普通決議案通過以來，公司在香港聯交所購回的證券總數達93,157,000股，佔已發行股份的2.19275%。药明生物確認，所有購回活動均符合《主板上市規則》/《GEM上市規則》的規定。
Pharmaceutical Biotechnology Co., Ltd. (Pharma Ming Biotech) completed a series of share repurchase activities on 19 April 2024 and disclosed the relevant changes to the Hong Kong Stock Exchange Limited the following day. The company repurchased shares through multiple transactions between December 7, 2023 and April 19, 2024, but did not write them off. The last repurchase took place on April 19, 2024. 1,570,000 shares were repurchased at a price of HKD 12.62 to HKD 12.8 for a total payout of HKD 19,920,430. Since the adoption of the Ordinary Resolution, the Company has repurchased 93,157,000 shares on the Hong Kong Stock Exchange, representing 2.19275% of the issued shares. Pharma Bio confirms that all repurchases comply with the provisions of the Main Board Listing Rules/GEM Listing Rules.
Pharmaceutical Biotechnology Co., Ltd. (Pharma Ming Biotech) completed a series of share repurchase activities on 19 April 2024 and disclosed the relevant changes to the Hong Kong Stock Exchange Limited the following day. The company repurchased shares through multiple transactions between December 7, 2023 and April 19, 2024, but did not write them off. The last repurchase took place on April 19, 2024. 1,570,000 shares were repurchased at a price of HKD 12.62 to HKD 12.8 for a total payout of HKD 19,920,430. Since the adoption of the Ordinary Resolution, the Company has repurchased 93,157,000 shares on the Hong Kong Stock Exchange, representing 2.19275% of the issued shares. Pharma Bio confirms that all repurchases comply with the provisions of the Main Board Listing Rules/GEM Listing Rules.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

The translation is provided by third-party software.


The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.